002821 Asymchem Laboratories
- 82.65
- -1.53-1.82%
Asymchem Laboratories News
Gloria Ying (002821): Small molecule business continues to grow and accelerate overseas layout
Gloria Ying (002821): Regular business is growing steadily, and emerging businesses continue to advance
Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy
Gloria Ying (002821): Regular business achieved steady growth in Q1, profit margins in line with expectations
Gloria Ying (002821) 2024 Quarterly Report Review: Overseas Customer Revenue Increased Rapidly, Profitability Remained Steady
Minsheng Securities released a research report on April 26 stating that it gave Gloria Ying (002821.SZ) a recommended rating. The main reasons for the rating include: 1) rapid revenue growth in the European and American markets, and continued deepening se
Gloria Ying (002821): Regular business is growing steadily, and overseas markets continue to improve
Gloria Ying (002821): 1Q24 endogenous routine income growth was steady
Gloria Ying (002821): Strong commercialization supports emerging businesses ready to go
Gloria Ying (002821): Market expansion efforts to increase investment in R&D of new technology platforms
Gloria Ying (002821): Steady growth on the revenue side, emerging business trends are optimistic about the long-term development of the company
Caixin Securities released a research report on April 8 stating that Gloria Ying (002821.SZ) was given a buying rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) the regular business grew rapidly
Gloria Ying (002821) 2023 Annual Report Review Report: Small-molecule CDMO routine business is growing steadily, new business capacity is being implemented at an accelerated pace
Gloria Ying (002821): Regular business is growing steadily, and emerging businesses continue to advance
Gloria Ying (002821): Performance is in line with expectations, optimistic about the future volume of emerging businesses
Gloria Ying (002821): Regular business grows steadily, and emerging sectors accelerate layout
Gloria Ying (002821): Steady development of conventional business, positive results in the construction of emerging sectors
Gloria Ying (002821): Regular business is growing steadily, and emerging sectors are under pressure in the short term
Gloria Ying (002821): Strong revenue growth in the commercialization phase, rich clinical project reserves
Gloria Ying (002821): Small molecule businesses are growing steadily, and emerging businesses are ready to go
Analysis
Price Target
No Data
